2015 Board of Directors Election

All members of the Metabolomics Society are welcomed and encouraged to participate in the 2015 Board of Directors election. Voting is open now through August 26, 2015 at 11:59pm USA CST. Complete details on the election and Board of Directors can be found here.

This webpage contains a list of nominees as well as biographies and statements of interest regarding serving on the Board. Please take a moment to review these details.

List of Nominees:

Standing for a second term:

New nominees:

How to Vote:

Each member has four (4) votes. You will need to enter your member email address to begin voting.
An e-mail was sent July 30, 2015 to all members containing the email address. If you cannot find your member email address, please contact This email address is being protected from spambots. You need JavaScript enabled to view it. for assistance.

vote here btn


Darren Creek (Standing for a second term)

Dr. Darren Creek is a NHMRC Career Development Fellow at the Monash Institute of Pharmaceutical Sciences, Parkville, Australia. Darren completed his PhD in pharmaceutics at Monash University in 2008, which involved applications of LCMS and spectroscopic methods to support the discovery of novel antimalarials, arterolane and OZ439. He then conducted post-doctoral research on clinical pharmacology of malaria with the University of California San Francisco and Makerere University in Uganda, and returned to Australia to investigate drug metabolism at the Centre for Drug Candidate Optimisation. On being awarded the NHMRC CJ Martin fellowship, Darren moved to Glasgow University, UK, where he played a major role in the implementation of the Scottish Metabolomics Facility. Darren has developed numerous analytical and bioinformatic methods to optimise outcomes from LCMS and GCMS based untargeted metabolomics studies, and his major contributions to the metabolomics field include: retention time prediction for metabolite identification, untargeted stable-isotope labelling for pathway discovery, and the user-friendly, open-source software for identification and evaluation of metabolomics data, IDEOM. His research has demonstrated the power of metabolomics for the unbiased discovery of novel enzymes, pathways and mechanisms of drug action, and he continues to develop metabolomics techniques, and apply metabolomics to parasitology, microbiology and cancer pharmacology. Darren has over 40 peer-reviewed publications and maintains several local and international collaborations to apply metabolomics to address important issues in biomedical research.

Contributions to the Board/Society during previous term: During my first term as director I attended all Board meetings and contributed significantly to improving the member benefits and outreach of the Society. As Chair of the Conferences and Training Committee I have assisted with improving the organisation structure for the annual Society Conferences, and implemented a new scheme to support small metabolomics meetings and workshops organised by members of the Society. Many of these sponsorships take the form of travel awards for Early-Career Members of the Society. I am an active member of the Metabolite Identification Task Group (see Creek DJ, et al. Metabolomics. 2014; 10(3): 350-353). As a member of the Nomination & Election Committee and the Industry Engagement Task Group I contribute to the future of this growing society.

Intended goals for a possible second term as a Director: My focus for the continued development of the Society involves training and networking opportunities, particularly for the younger members of the metabolomics community. If re-elected I will continue to advance the professional organisation of the Society's annual conference to ensure consistently high quality conferences as the metabolomics community continues to expand. I will also push for greater collaboration with related disciplines to support additional smaller, more focused, conferences to expand the application of metabolomics throughout the biochemical sciences. I will support the community-led improvement of metabolomics standards through the Society Task Groups, with a specific focus on metabolite identification.

Back to top


David Iain Broadhurst

Dr. David Broadhurst (www.davidbroadhurst.net), born Chester UK, holds a first class honours degree in Electronic Engineering, an MSc in Medical Informatics, and a PhD on the subject of ''Application of Artificial Neural Networks and Evolutionary Algorithms to Metabolic Profiling''. He has been an active member of the metabolomics community for the last 18 years, where he is a recognized expert in design of experiments, signal processing, biostatistics, and machine learning. David worked for an extended period as a post-doctoral research fellow developing large-scale clinical metabolomics protocols alongside Dr. Warrick Dunn, at the University of Manchester as part of Professor Douglas Kell's Bioanalytical Sciences Group. In 2009 he moved to Cork University Maternity Hospital, Ireland, to investigate pre-symptomatic metabolite biomarkers predictive of major pregnancy diseases. In January 2011 David took up his current position as Associate Professor of Applied Biostatistics in the department of Medicine, at the University of Alberta, Canada, where he is scientific lead and academic coordinator for a range of clinical metabolomics, and integrated pan-omic, personalized medicine projects. His current research primarily focuses the application and optimization of diverse multivariate modelling techniques (parametric & non-parametric linear models, decision trees, machine learning, Structural Equation Modelling, Multilevel random-effects models, etc.) within the domain of systems-biology. Additionally, he has research interests in data visualization, design of experiments, and developing quality assurance procedures for 'omic based studies. David travels extensively around the globe lecturing on the perils of poor experimental design and importance of robust and diverse statistical analysis.

Statement of Purpose: Dr. David Broadhurst is standing for election to the Metabolomics Society board of directors primarily on the platform of promoting and educating existing and most importantly junior members of the metabolomics community with regard to design of experiments and rigorous statistical protocols. He is an advocate of the development of, and international adherence to, a clear set of standardized quality assurance protocols ensuring that high quality repeatable metabolomic studies will lead to precise and scientifically legitimate biological inference. David is a particular advocate for formalizing a society-based accreditation of metabolomics workshops/short courses, and the development of accredited online metabolomics educational media. Through education, empowerment, and excellence, the future of metabolomics as a credible science will be assured.
Back to top


Choong Hwan Lee

Choong Hwan Lee obtained his Ph D from the Seoul National University in 1996. After his natural product researcher period in Scripps Institution of Oceanography, UC-San Diego and principal researcher period at KRIBB (Korea Research Institute of Bioscience and Biotechnology), he moved to Konkuk University in 2006. Science 2011, he participated in Metabolomics Society as an International Scientific Advisory Board. Since 2012, he has been appointed as a Founding Secretary of Korea Metabolomics Society (KoMeTs). He elected as president of KoMeTs (2016-2017). His research interest is metabolomic interpretation of primary and secondary metabolism with in vivo efficacy study of natural product.

Statement of Purpose: In 2012, I with my colleagues founded Korea Metabolomics Society with permission of Korea Government and held 1st Korea Metabolomics Society (KoMeTS, http://www.komets.or.kr) Meeting with 450 participants in Seoul, Korea. As the next president of KoMeTS, I with communicate with other countries by making regional network for booming up society. 
Back to top


Tuulia Hyötyläinen

Dr. Tuulia Hyötyläinen obtained a MSc degree in Chemistry at The University of Helsinki in Finland followed by a PhD in Analytical Chemistry in 1998. She has been working at University of Helsinki, first as post doc researcher, then as an Academy of Finland Fellow and as an acting professor. Currently she is working as Principal Investigator at Steno Diabetes Center in Denmark, leading the metabolomics laboratory; as well as group leader at the Turku Centre for Biotechnology (Finland). Dr. Hyötyläinen has a broad background in separation science, particularly in hyphenated and multidimensional chromatographic methods combined with mass spectrometric techniques. Dr. Hyötyläinen has published over 130 peer-reviewed papers as well as several books and book chapters. She has been involved as organizer and board member in multiple international conferences and societies in the field of analytical chemistry. Over the past years her main research focus has been in the development of methods for metabolomic analyses, both for non-targeted profiling methods in discovery, as well as for targeted analysis of specific key metabolites. One of the main aims of her research has been the development of robust workflows from sampling, sample preparation, analysis to data preprocessing and data mining, and quality control of the each step of the workflow, suitable for large scale analysis of clinical samples. Development of methodologies for the identification of unknown metabolites has also been one of the main aspects of the research. Currently, one of her main goals is to develop targeted metabolomics protocols to be used in daily clinical practice.

Statement: I hope to contribute to the Metabolomics Society my organizational skills and extensive analytical experience as related to metabolomics. In metabolomics field, I would like to enhance the collaborative efforts to develop methodologies and guidelines for quality control in sampling, sample preparation and analysis as well as metabolite identification, especially in clinical metabolomics in order to facilitate large-scale comparative analyses in this field.

Back to top


Oliver Jones

Dr. Oliver (Oli) Jones is a senior lecturer in analytical chemistry at RMIT University in Melbourne, Australia. He obtained his PhD in environmental chemistry from Imperial College London in 2005, and was introduced to metabolomics while working as a postdoc at the University of Cambridge with Dr. Jules Griffin. He later worked as a lecturer in the School of Engineering and Computing Sciences at the University of Durham before moving to RMIT in 2012. Oli is currently president of the Australian and New Zealand Metabolomics Network (for whom he writes a weekly newsletter) that was the first international affiliate of the metabolomics society. He is co-president of Proteomics and Metabolomics Victoria, secretary of the Australian and New Zealand Society for Magnetic Resonance, a CI at the Australian Centre for Research on Separation Science and a member the Australian Academy of Science, National Committee for Chemistry. He is also deputy director of the RMIT Centre for Environmental Sustainability and Remediation and has helped organise several conferences. Aside from metabolomics, his group also conducts research in analytical methods and technologies, particularly in multidimensional chromatography and NMR. He has 55 publications with a total of over 2300 citations and an h-index of 18.

Statement of Purpose: I have been involved in metabolomics for almost ten years. I started out as a postdoc in environmental metabolomics at Cambridge University where I investigated the cumulative effects and risks to organisms from exposure to complex mixtures of chemicals and later, also looked at the effects of mixtures of pesticides in food. During this time I published the first metabolic profiles of several ecologically important species and helped to draft the standard reporting requirements for biological samples in metabolomics experiments in the environmental context. Currently I am working on developing the use of two-dimensional liquid chromatography for metabolomics, work that won an outstanding investigator award at the last Metabolomics Society conference.

I would like to serve as a director to give something back to the society and the field. I have a large amount of experience in organisation though my roles in various other societies. This experience will help me hit the ground running and play an active role in both administrative and scientific activities of the society if elected. I am particularly interested to raise the profile of metabolomics on the international scientific stage. The society could perhaps award a medal for outstanding research in metabolomics each year for example as well as provide more videos and education material on the website to help new entrants to the field. I am keen to continue my work developing new analytical methodologies for metabolite separation and identification. If elected I would also try to develop more interaction with the other omic sciences, so as to move towards a more integrated approach to understanding biological systems.
Back to top


Annick Moing

Dr. Annick Moing gained an Engineer Diploma in Agronomy (ENSA Montpellier, France) and a PhD in Plant Science (University of Bordeaux, France) and has subsequently completed 28 years research experience. After working on whole plant physiology, quantitative genetics and fruit metabolism, her primary research activities are now centered on developing metabolomics technologies for application in plant genetics, functional genomics and systems biology for the study of fruit and grain quality. She leads the Metabolome Facility of Bordeaux Functional Genomics Centre (www.cgfb.u-bordeaux2.fr/en/metabolome) implicated in several research areas and is involved in the constitution of a French National Metabolomics infrastructure (www.metabohub.fr). Her group is also involved in data integration, NMR spectra processing and databases. She has completed about 70 publications in peer reviewed journals and 7 book chapters. She is on the Editorial Board of the journal Metabolomics.

Statement of Purpose: Our Metabolome Facility in Bordeaux has been considered a pioneer in the development of plant metabolomics in France. During my entire career I have been working at the interface of different disciplines of plant sciences, developing collaborations and synergies, and continue to do so with metabolomics approaches on a wider view in several research areas.
I have expressed interest to join the Board of the Metabolomics Society for a few years for several reasons. I wish to use my experiences in metabolomics for my personal research goals as well as for the numerous collaborations and services developed by our Metabolome Facility to: (i) represent the French and francophone metabolomics community (about 230 people at the last Metabolomics Meeting organized by the French Metabolomics and Fluxomics Network), and further develop the connection between this community and the Society, (ii) contribute to the ongoing standardization initiatives that remain crucial for our international community, (iii) stimulate synergies between biologists, chemists and bioinformaticians by participating in decisions and initiatives lead by the Society including those concerning training, networking and communication.
Back to top


Robert Powers

Dr. Robert Powers is currently a Professor of Chemistry at the University of Nebraska-Lincoln. Dr. Powers received his BA in Chemistry from Rutgers University in 1984 and completed his Ph.D. in chemistry at Purdue University in 1989. His postdoctoral work was with Drs. G. Marius Clore and Angela Gronenborn at the National Institutes of Health laboratory of Chemical Physics. After completing his post-doctoral IRTA fellowship, Dr. Powers joined American Cyanamid in 1992 which was acquired by AHP in 1994 followed by a merger with Genetics Institute in 1998 to form Wyeth. Dr. Powers was an Associate Director for the Protein NMR group before arriving at UNL in 2003. Recently, Dr. Powers' research has focused on the development of NMR- and MS-based metabolomics as a tool for systems biology, drug discovery and, for the discovery of disease biomarkers. This effort has included the MVAPACK metabolomics software platform and the integration of NMR and MS datasets. Dr. Powers has applied his NMR and MS metabolomics methodologies to a variety of human health issues that include pancreatic cancer, Parkinson's disease, multiple sclerosis, and staph and TB infections. Dr. Powers is currently the Editor-in-Chief of Current Metabolomics, on the editorial board of five other journals, is a founding member of the International Chemical Biology Society, was the recipient of the ACS Outreach Volunteer of the Year in 2014, and has written over 110 peer-reviewed manuscripts, 5 book chapters, and is an inventor on 9 patents (h-index 32 with 3,754 citations).

Statement of Purpose: In order for metabolomics to continue to grow at an impressive rate, to continue to expand into a diversity of fields, and to achieve its potential, metabolomics must maintain its image of reliability and accuracy. As a member of the Metabolomics Society Board of Directors I will help to continue to establish and promote the broad adaption of standards for the design of metabolomics studies, for reporting of metabolomics data, and for the statistical validation of metabolomics models. Secondly, in order for metabolomics to continue to evolve, it must move away from an analytical-method focused (e.g., GC-MS, LC-MS or NMR, etc.) approach. Instead, the emphasis should be on a thorough and accurate analysis of the metabolome, where the choice of multiple analytical techniques is obvious and routine. As a board member, I will help the Metabolomics Society promote this perspective. The continued growth of metabolomics depends on new and young investigators. In addition to the workshops, the Metabolomics Society would benefit from enabling and promoting our young investigators. One approach I would endorse is to dedicate a series of talks at the annual society meeting to presentations from post-doctoral students and recently appointed assistant professors. Simply, as a Board Member I will work hard to contribute to the continued success of the Metabolomics Society and the field of metabolomics.
Back to top


Sastia Prama Putri

Sastia Prama Putri is an assistant professor at the Department of Biotechnology, Graduate School of Engineering, Osaka University. She received her PhD from International Center for Biotechnology, Osaka University. Sastia joined a metabolomics laboratory in the same university under Prof. Eiichiro Fukusaki in 2011 and her current research interest is the application of metabolomics technology for optimizing biofuel production and food metabolomics studies focusing on food authentication and quality evaluation. Her awards include the "Metabolomics Australia Poster Prize" in the 9th Annual Conference of the Metabolomics Society, Glasgow, UK", a research fellowship from UNESCO and scholarship from the Japanese Government. She is currently the Chair of the Early-career Members Network (EMN) of the Metabolomics Society and with this position, she has been serving as an ex officio board member of the Metabolomics Society since 2013. In addition to performing research and teaching, she is also working for the Osaka University Center for the Advancement of Research and Education exchange Network (CAREN). This position enables her to establish a strong academic network with partner universities for establishing academic and research exchanges, particularly with top universities in Asia Pacific region.

Statement of Purpose: As the founding Chair of the Early-career Members Network (EMN) of the Metabolomics Society, I have been involved in leading the three main activities of EMN: a) organizing workshops that are tailored to the needs of early-career members, b) arranging social networking events in the annual meeting of the Society, and c) establishing and coordinating the webinar series of the Society. As the EMN Chair, I also serve as an ex officio board member and participate as a member in the Conference and Training committee as well as the Strategy task group of the Society. With two years of experience to lead the EMN and active participation in various task groups in the Society, I am confident that I could contribute in the Society's activities in a wider scale. If elected, my main goals as Director will be to work closely with the EMN committee members to establish a real sense of community and engagement between early career researchers globally and to extend and strengthen the Society's partnerships with regional metabolomics communities and networks, particularly in Asia Pacific region. I am also passionate to actively promote the field of metabolomics in my home country, Indonesia as well as other countries in Southeast Asia by organizing and supporting various regional workshops on metabolomics.
Back to top


Daniel Raftery

Dan Raftery is currently a Medical Education and Research Endowed Professor at the University of Washington, School of Medicine, and is a Member of the Fred Hutchinson Cancer Research Center in Seattle. Previously, he was Professor of Analytical and Physical Chemistry at Purdue University for almost 18 years. He currently directs the Northwest Metabolomics Research Center at UW Medicine, and is the founder and Chief Scientific Officer of Matrix-Bio, Inc. Dr. Raftery has been active in metabolomics since 2003, focusing on the development of advanced and novel methods such as NMR/MS smart isotope tagging, as well as novel statistical methods for unknown identification and metabolite modeling. His group is also interested in identifying early biomarkers and metabolic risk factors for a number of cancers and other diseases, and for the exploration of systems biology.

Statement of Purpose: While metabolomics has developed rapidly in a broad range of areas with great impact, a number of bottlenecks impede progress and will require improvement, such as data reliability, metabolome coverage, quantitation, and reporting. The Society can play an important role in shaping such efforts and disseminating results and progress in these and related areas. Given my broad background in analytical chemistry and my role in leading the Northwest Metabolomics Research Center, I have a breadth of experience to help the Metabolomics Society's efforts in its committees and working groups. These efforts will provide society members with the information to improve their metabolomics capabilities, studies and results.
Back to top


Michael Reily

I received my B.S. in Chemistry from the University of West Florida and Ph.D. in Bioinorganic Chemistry from Emory University in 1986, followed by a sharpening my expertise in biomolecular NMR skills as a post doc with John Markley at Wisconsin. From there, I joined Parke-Davis (eventually becoming Pfizer) in Ann Arbor MI, where I applied NMR spectroscopy to drug discovery and development in areas of medicinal chemistry, protein structure determination and metabolite structure elucidation. In 1998, I conducted my first "biofluid NMR" experiment and was immediately hooked on what would become the field of metabonomics/metabolomics. Over the next few years, I abandoned my other research interests to focus on metabolomics set my sights on making mass spectrometry a secondary expertise. I joined Bristol-Myers Squibb in September of 2007 as a Research Fellow where I manage the Discovery Analytical NMR group and serve as the matrix leader of the Applied and Investigational Metabolomics team. I am a member of the American Chemical Society, the Metabolomics Society and am author or co-author on approximately 90 peer-reviewed journal articles and book chapters.

Statement of Purpose: Metabolomics research is in an exponential growth phase and occurs across a wide demographic, with a variety of specific applications. There is significant metabolomics work going on in the pharmaceutical industry, but limited representation in the Society. As a member of the board, I will work with my counterparts at other companies to provide representation of and greater participation from for our industry. I strongly feel that both NMR and MS are crucial to successful metabolomics deployments and have a long history of integrating both technologies within my industry and will bring that philosophy to the Board.
Back to top


Mark Styczynski

Mark is an Assistant Professor entering his seventh year in the School of Chemical & Biomolecular Engineering at Georgia Tech. He has been a leader in the formation of the North American Metabolomics Chapter, which had its inaugural meeting at the annual conference this year. His research group's focus is on studying the dynamics and regulation of metabolism, using time-course metabolomics and computational approaches to gain deeper insight into metabolic processes. He also applies synthetic biology to metabolism-relevant problems. He received his Ph.D. from MIT in 2007, applying pattern discovery tools to GC-MS data analysis problems in metabolomics. He was a postdoctoral fellow at the Broad Institute from 2007-2009, where he did metabolomics work on numerous yeast species. His work has been published in numerous systems biology and chemistry journals, including Nature Biotechnology, Analytical Chemistry, Metabolic Engineering, and Molecular BioSystems.

Statement: My main goal as a Director would be to encourage the growth of the Society and the sustainability of its influence. I would obviously take on any task or role needed of me during my time as a Director, but the things that I think would particularly contribute to these goals include (1) increasing the Society's inclusiveness of related applications of metabolomics and (2) encouraging the development and close association of regional metabolomics organizations. On the inclusiveness front, I think there are a number of fields that are underrepresented in the Society that contribute to the breadth and depth of the impact of metabolomics, and that we should make significant efforts to reach out to those researchers; these fields include lipidomics, fluxomics, and food science, among others. On the regional associations front, I believe that maintaining as close a relationship as possible with regional metabolomics groups would be beneficial to all parties: the Society can provide guidance, support, a centralized interface with other regional groups, and even resources when possible, while the regional groups provide the opportunity for a more direct and substantial impact of the Society's efforts. I have been helping to lead the development of a new "Chapter" model for the relationship between the Society and regional groups, with the expected formalization of this agreement for a North American chapter by this fall. To that end, I would advocate for the interests of regional metabolomics groups as a whole, and would look to get involved with the International Affiliations Task Group.

Back to top


Merlijn van Rijswijk

I am managing director of the Netherlands Metabolomics Centre, a public-private research initiative that has acquired over € 25 million in government funding. My background is in science (MSc in in bio-organic chemistry Utrecht University and postgraduate education in biotechnology at Delft University of Technology) combined with a MBA of the Erasmus Business School recently.

Working in public-private organizations is a thread throughout my career. After graduation I joined the Ministry of Economic Affairs and was active in managing and setting up new public-private research programs and served as a policy advisor in Life Sciences, Innovation, Foresight, and Entrepreneurship. Furthermore I participated on behalf of the Netherlands' government in several European Research programs and I was a project leader supporting a think tank of the Dutch Prime Minister on Innovation and Competitiveness.

Statement of Purpose: More standardization is key to advance the field of Metabolomics. We therefore need to take as a community global initiatives involving leading research groups and facilities to compare methods, and to develop and implement standards both in analytical methods and data processing. In addition I believe there is a lot of benefit to be gained from increasing collaboration with pharma, biotech and the food industry, to get the groundbreaking metabolomics research applied in new products and processes, thereby also creating new funding opportunities for academic research. Furthermore, I want to achieve more coordination in education and training activities, in lobbying towards new funding opportunities (at NIH, European Commission, national organizations and NGOs) and communication to the society at large. Furthermore I strongly believe in integrated life sciences, combining metabolomics with other "omics" technologies and imaging. The Metabolomics Society is a natural platform to take initiative to achieve these goals.

During the last Metabolomics Society conference in San Francisco I was elected chairman of the newly set up International Affiliates Task Group. This task group is to encourage more collaboration between regional and international metabolomics organizations. One of my objectives for the next year is to evaluate if there is support and added value in setting up a European Chapter under the umbrella of the Metabolomics Society. I hope to bring added value to the Board of Directors with my organizational skills and background as manager of public-private partnerships. My candidacy is supported by the Board of the Netherlands Metabolomics Foundation.
Back to top

 


Ron Wehrens

Ron Wehrens obtained a PhD in Chemometrics in 1994 at the University of Nijmegen, the Netherlands. He subsequently held positions at the universities in Twente and Nijmegen. In 2010 he moved to the Fondazione Edmund Mach in Italy, where he founded the Biostatistics and Data Analysis group. Since 2014 he is back in the Netherlands as Business Unit Manager at the Wageningen University and Research Centre, leading the contract research group at Biometris. His scientific interests include statistical modeling, clustering, classification, chemometrics and statistical software (in particularly R). He is author of over 90 ISI publications and one monograph.

Statement of Purpose: Apart from supporting the Metabolomics Society and community in general, specific goals would be:
- to promote high-quality and reproducible research in metabolomics. This includes attention for FAIR data principles, and the development of (open-source) software.
- help the dissemination of good practices in data analysis among young researchers: there is an important educational task here.
- open up the field of metabolomics for small and medium enterprises: in my current work I see that the field of metabolomics is still rather unknown in many smaller companies, and that facilities are not always easily accessible.
Back to top


William Wikoff 

Bill Wikoff obtained his PhD from Purdue University in 1998 in Biophysics, and did a postdoc at The Scripps Research Institute, followed by a faculty position at Washington University School of Medicine. Switching fields from Structural Biology to Metabolomics in 2005, he is currently a senior scientist in the Genome Center at University of California Davis. He has extensive experience in using mass spectrometry and metabolomics to investigate human health and disease. Areas of active research interest include the epilepsy, Alzheimer's disease and other neurological diseases, and lung cancer, as well as human and mouse gut microbiome and its relation to health. He has been a founder and chair of the ABRF metabolomics working group and a co-chair of the ASMS metabolomics workshop for three years, as well as a number of metabolomics committees. He has taught many short courses in metabolomics since 2005.

Statement: I will provide a fresh perspective, vision and energy to the metabolomics society board. It is important that the metabolomics society engages the broader scientific community, particularly to reach out to more biologists and biomedical researchers who may be interested in the field of metabolomics. The society should continue to expand while striving to develop a more engaged and active membership. There are many ways for this to occur beyond the annual meetings. I will move for increased metabolomics society engagement on the following important issues: improved standards for metabolomics publishing (for example clear publication standards for compound identification) and community standards for data deposition, including encouraging journals to require data deposition for publication.

Back to top


Krista Zanetti

Krista Zanetti is a Program Officer in the Epidemiology and Genomics Research Program (EGRP), Division of Cancer Control and Population Sciences at the National Cancer Institute (NCI), National Institutes of Health (NIH). Dr. Zanetti earned her Ph.D. in Nutrition in 2003 and joined the Cancer Prevention Fellowship Program at the NCI. During the first year of her fellowship, she earned an M.P.H. at the Johns Hopkins Bloomberg School of Public Health. Dr. Zanetti then conducted primary research in the Laboratory of Human Carcinogenesis in the NCI's Center for Cancer Research from 2004 to 2010.
Since joining EGRP in 2010, Dr. Zanetti's primary focus has been building infrastructure and capacity to support metabolomics in large population-based studies. Most recently, she spearheaded collaborative efforts to establish the trans-NIH international Consortium of Metabolomics Studies (COMETS) that brought together 24 prospective cohorts and 3 well-established consortia from the U.S., Europe and South America. COMETS will allow investigators from across multiple disease phenotypes to: 1.) leverage existing resources and data; and 2.) work collectively to develop methods, tools and protocols for data harmonization and sharing, quality control and data standardization.

Statement: The field of metabolomics is rapidly evolving and broadening its reach. In recent years, metabolomics has been increasingly applied in ever larger human studies. Therefore, I would like to use my expertise in epidemiology to further advance the use of metabolomics in population-based research. I am particularly interested in tackling challenges related to big data (harmonization, standardization, integration, and sharing of data), as well as ensuring quality in biospecimen collection and storage. To address these issues, it will take a collaborative effort across the Metabolomics Society, academia, industry, and government.
If elected, my goals for my term on the Board are to: 1.) work with key scientific stakeholders to identify and prioritize challenges in the field and develop strategies to address them; 2.) further broaden the reach of the Metabolomics Society by engaging population-based researchers and other clinically-related scientists; and 3.) develop effective strategies to train the next generation of investigators in the field. Given my experience in establishing COMETS, I am well-poised to move the first two goals forward. Furthermore, I have been working with and advising the Early-career Member Network Committee for over a year and am enthusiastic to continue in this role in a more formalized manner as part of the Board.

Back to top